BioSpace News Archive

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in a Phase 1 trial evaluating ALLO-715

IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the appointment of George A. Gauthier to the newly created position of Chief Commercial Officer.

Breakthrough PPMO Technology Delivers High Levels of RNA Therapeutic Throughout the Brain Company Actively Progressing Discovery Activities in Neurodegenerative Diseases and Remains on Track to Nominate a CNS Development Candidate In 2021

- Ritter is a fast-growing, technology leader in high-precision consumables - Combines Ritter’s liquid handling consumables platform for clinical diagnostic testing and life sciences research with Avantor’s offerings for critical lab automation workflows and leading global customer channel

Raised aggregate gross proceeds of $40 million Depositary shares represent an interest in 8.375% Series B Cumulative Perpetual Preferred Stock

Our research has demonstrated that the phosphodiesterase type 1 (PDE1) enzyme modulates the immune system by reducing macrophage and microglial activity with demonstrated effects in neuroinflammatory conditions, cancer and cardiac diseases. Preclinical findings describing the antitumor effects of PDE1 Inhibitors when administered in conjunction with checkpoint inhibitor immunotherapy are being presented at the American Association for Cancer Research (AACR) virtual annual meeting.

The Company’s Virtual Presentation is Scheduled at 1:00 pm – 1:25 pm EST on April 20th, 2021

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data related to the optimization of CK-3773274 (CK-274), including the first disclosure of its chemical structure, were presented at the American Chemical Society Spring 2021 Virtual Meeting.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it has appointed Carter Ward as Chief Financial Officer, effective May 15 th , 2021.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the hiring of Steven E. Pfanstiel as Chief Financial Officer and Lisa Lejuwaan